Clinical Trial Update: Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood [Phase 2]

View source ↗

Summary

Phase 2 trial of imatinib mesylate in relapsed or refractory pediatric solid tumors has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Desmoplastic Small Round Cell Tumor
• Ewing Sarcoma
• Gastrointestinal Stromal Tumor
• Lung Metastasis
• Neuroblastoma
• Osteosarcoma
• Soft Tissue Sarcoma
• Synovial Sarcoma

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Desmoplastic Small Round Cell Tumor, Childhood Synovial Sarcoma | Phase 2 | Status: COMPLETED